ClinConnect ClinConnect Logo
Search / Trial NCT00581984

McGhan Medical Silicone-Filled Breast Implant Adjunct Study

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Dec 21, 2007

Trial Information

Current as of June 25, 2025

Completed

Keywords

Breast Cancer Breast Reconstruction Silicone Implants

ClinConnect Summary

This prospective clinical study is being undertaken to document the safety of McGhan Medical Silicone-Filled Breast Implants. Patients will be evaluated pre-operatively, intraoperatively, and at one, three and five years following implant surgery. Safety of McGhan Medical Silicone-Filled Breast Implants will be assessed based on the incidence of medical complications, implant failure and serious adverse effects.

This prospective clinical study of McGhan Medical Silicone-Filled Breast Implants is part of an ongoing research effort to document the safety and effectiveness of silicone-filled ...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Females of any age for which breast reconstruction is considered appropriate. (Patients under 18 years old require parental/legal guardian consent to participate).
  • * Have any of the following conditions or situations present:
  • Post mastectomy surgical removal of the breast for cancer or other diseases;
  • Post trauma or post surgery where there was total or partial removal of the breast resulting in significant deformity.(for any reason);
  • Severe ptosis requiring reconstruction (i.e. mastopexy);.
  • Any congenital or acquired discrepancy in breast size such as to represent a significant physical deformity. This does not include normal variants of asymmetry. Examples include, but are not limited to:Pectus excavatum, Pectus carinatum; Thoracic hypoplasia (Poland's syndrome, Scoliosis; Isolated rib deformities; Tuberous breasts; Congenital absence
  • Revision of implant procedure due to any of the following circumstances;
  • Previous augmentation or reconstruction with silicone- or saline-filled implants where problems exist, such as implant. rapture or significant capsular contracture (Baker Grade III or IV) requiring revision;
  • Contralateral mammaplasty in unaffected breast as a result of the affected breast requiring surgery (for one of the aforementioned circumstances), when medically indicated to provide symmetry.
  • Adequate tissue available to cover implants.
  • Saline-filled implants are not an appropriate choice.
  • Willingness to follow all study requirements, such as agreeing to all required follow-up visits, and acceptance of the risks involved as indicated by signing of the Patient Informed Consent document.
  • Exclusion Criteria:
  • Advanced fibrocystic disease considered to be premalignant-without accompanying subcutaneous mastectomy.
  • Existing carcinoma of the breast, without mastectomy.
  • Abscess or infection in the body at the time of enrollment.
  • Pregnant or nursing.
  • Have any disease, including uncontrolled diabetes; which is clinically known to impact wound healing ability.
  • Show tissue characteristics which are clinically incompatible with mammaplasty, such as tissue damage resulting from radiation, inadequate tissue, compromised vascularity or ulceration.
  • Have, or under treatment for, any condition which, in the opinion of the surgeon, may constitute an unwarranted surgical risk.
  • Show psychological characteristics which, in the opinion of the surgeon, may be incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation.
  • Wish to have augmentation mammaplasty, but do not have at least one of the diagnoses identified in Patient Inclusion Criteria item G #2, pages 7 \& 8.
  • Are not willing to undergo further surgery for revision, if medically required.
  • Diagnosis of lupus or scleroderma.
  • Replacement of saline-filled implants solely for a less than desirable cosmetic outcome, such as wrinkling.

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Peter Cordeiro, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials